Theranos blood-testing fraud

Theranos marketed a compact blood-testing device that promised fast, inexpensive diagnostics. Investigations later revealed that most tests were performed on conventional analyzers, and internal reports raised concerns about accuracy.

Regulators and prosecutors alleged that misleading claims about the technology and business performance were used to raise capital from investors. Civil enforcement actions and criminal proceedings followed.